ANTIDEPRESSANTS. Details. Step Therapy 2018 Last Updated: 8/21/2018

Similar documents
ANTIDEPRESSANTS. Details. Step Therapy 2017 Last Updated: 5/23/2017

DIFICID. Products Affected Step 2: DIFICID TABLET 200 MG ORAL. Details

ABILIFY INJ. Products Affected Step 2: ABILIFY MAINTENA PREFILLED SYRINGE 300 MG INTRAMUSCULAR ABILIFY MAINTENA PREFILLED SYRINGE 400 MG INTRAMUSCULAR

CARE N CARE HEALTH PLAN

ARISTADA. Products Affected Step 2: ARISTADA PREFILLED SYRINGE 1064 MG/3.9ML INTRAMUSCULAR ARISTADA PREFILLED SYRINGE 441 MG/1.

HEALTHTEAM ADVANTAGE 2018 Step Therapy Criteria

PPHP 2017 Formulary 2017 Step Therapy Criteria

HEALTHTEAM ADVANTAGE 2018 Step Therapy Criteria

CARE N CARE HEALTH PLAN

CARE N CARE HEALTH PLAN

**CRITERIA UNDER CMS REVIEW**

BRINTELLIX. Step Therapy Criteria HealthTeam Advantage Formulary ID: Version 6 Effective Date: 1/1/2016. PRODUCT(s) AFFECTED BRINTELLIX

ANTICONVULSANTS. Details. Step Therapy Criteria Date Effective: April 1, 2019

HEALTHTEAM ADVANTAGE PLAN 2017 Step Therapy Criteria Pending CMS Approval

Step Therapy Medications

CRITERIA Trial of two generic formulary products from the following: atomoxetine or ADHD stimulant medication.

Biologic Immunomodulators Prior Authorization with Quantity Limit Program Summary

U T I L I Z A T I O N E D I T S

2015 Step Therapy Prior Authorization Medical Necessity Guidelines

Step Therapy Group. Atypical Antipsychotic Agents

VNSNY CHOICE FIDA Complete Step Therapy Requirements. Effective: 01/01/2017

ALPHA GLUCOSIDASE INHIBITOR THERAPY

ANTICONVULSANTS. Details

Step Therapy Requirements

ANTICONVULSANTS. Details

FirstCarolinaCare Insurance Company. Step Therapy Requirements

Santa Clara Family Health Plan Cal MediConnect Formulary. List of Step Therapy Requirements Effective: 12/01/ E

ANTICONVULSANTS. Details

WELLCARE/ OHANA HEALTH PLAN 2015 STEP THERAPY CRITERIA (No Changes Made Since: 08/2015)

ANTICONVULSANTS. Details

AMANTADINE ER. Products Affected Step 2: OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, Details

1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.

JANUVIA 50 MG TABLET BYDUREON 2 MG/0.65 ML JARDIANCE 10 MG TABLET SUBCUTANEOUS PEN INJECTOR JARDIANCE 25 MG TABLET BYDUREON BCISE 2 MG/0.

Granite Alliance Insurance Company (PDP) 2018 Step Therapy Criteria Last Updated: 10/23/18

Texas Prior Authorization Program Clinical Edit Criteria

Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases

ANTIDEPRESSANTS. Details. dose pack Viibryd 10 mg tablet Viibryd 20 mg tablet Viibryd 40 mg tablet. Criteria

Step Therapy Requirements. Effective: 1/1/2019

ADHD STIMULANTS-S(SHC)

AMANTADINE ER. Products Affected Step 2: OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, Details

Step Therapy Requirements. Effective: 11/01/2018

AMANTADINE ER. Products Affected Step 2: OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, Details

Step Therapy Requirements. Effective: 05/01/2018

Harvard Pilgrim Health Care Stride SM Basic Rx (HMO), Stride SM Value Rx (HMO) and Stride SM Value Rx Plus (HMO) Step Therapy Requirements

ANTIDIABETIC AGENTS - MISCELLANEOUS

Harvard Pilgrim Health Care Stride SM Basic Rx (HMO), Stride SM Value Rx (HMO), Stride SM Value Rx Plus (HMO) and Stride SM Gain Rx (HMO)

ANTIDIABETIC AGENTS - MISCELLANEOUS

VNSNY CHOICE FIDA Complete Step Therapy Requirements. Effective: 01/01/2017

Step Therapy Criteria 2019

2018 STEP THERAPY CRITERIA UCare Connect (SNBC) MinnesotaCare Prepaid Medical Assistance Program (PMAP) Minnesota Senior Care Plus (MSC+)

ANTIDIABETIC AGENTS - MISCELLANEOUS

ACTEMRA (tocilizumab)

2018 Step Therapy Criteria

Judges Reference Table for the March 2016 Psychotropic Medication Utilization Parameters for Foster Children

Simply Step Therapy Document September 2018 Y0114_18_33074_I_009

Step Therapy Requirements. Effective: 03/01/2015

ACYCLOVIR OINT (CCHP2017)

Antipsychotics Prior Authorization Criteria for Louisiana Fee for Service and MCO Medicaid Recipients

INFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Ixifi* (infliximabqbtx), Renflexis (infliximab-abda)

VNSNY CHOICE FIDA Complete Step Therapy Requirements. Effective: 04/01/2019

Drugs requiring prior authorization: the list of drugs requiring prior authorization for this clinical criteria

Pharmacy Management Drug Policy

Pharmacy Formulary Updates for January 2019

These programs and quantity limitations may not apply. Check your certificate or other plan information for benefit details.

Memorial Hermann Advantage HMO February 2019 Formulary Addendum

Otezla. Otezla (apremilast) Description

Regulatory Status FDA-approved indication: Orencia is a selective T cell co-stimulation modulator indicated for: (1)

Regulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1)

Regulatory Status FDA-approved indications: Entyvio is an α4β7integrin receptor antagonist indicated for: (1)

ALLERGIC CONJUNCTIVITIS AGENTS

2018 Step Therapy FID 18088

2019 Simply Step Therapy Document

Medications and Children Disorders

Medicare Part D Drugs that Require Step Therapy Effective 12/01/2017

Regulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1)

ACYCLOVIR OINT (CCHP2017)

ANGIOTENSIN RECEPTOR BLOCKERS STEP THERAPY

2017 Step Therapy Criteria

Step Therapy Criteria

2019 PDP Basic Step Therapy Document

IMPORTANT NOTICE. Changes to dispensing of some Behavioral Health Medications for DC Healthcare Alliance members

Attention: Behavioral Health Providers, Pharmacists and Prescribers N.C. Medicaid and N.C. Health Choice Preferred Drug List Changes - UPDATE

Xeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description

Step Therapy Criteria

Relative Cost/Month. Less than $10. Loratadine Liquid* $10-$15 Cetirizine liquid 1mg/mL*

2016 Step Therapy (ST) Criteria

Pre - PA Allowance. Prior-Approval Requirements LEVORPHANOL TARTRATE. None

Immune Modulating Drugs Prior Authorization Request Form

Transcription:

ANTIDEPRESSANTS EMSAM PATCH 24 HOUR 12 MG/24HR TRANSDERMAL EMSAM PATCH 24 HOUR 6 MG/24HR TRANSDERMAL EMSAM PATCH 24 HOUR 9 MG/24HR TRANSDERMAL FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 120 MG ORAL FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 20 MG ORAL FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 40 MG ORAL FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 80 MG ORAL Step Therapy 2018 Last Updated: 8/21/2018 FETZIMA TITRATION CAPSULE ER 24 HOUR THERAPY PACK 20 & 40 MG ORAL MARPLAN TABLET 10 MG ORAL PAXIL SUSPENSION 10 MG/5ML ORAL PEXEVA TABLET 10 MG ORAL PEXEVA TABLET 20 MG ORAL PEXEVA TABLET 30 MG ORAL PEXEVA TABLET 40 MG ORAL TRINTELLIX TABLET 10 MG ORAL TRINTELLIX TABLET 20 MG ORAL TRINTELLIX TABLET 5 MG ORAL Claim will pay automatically for MARPLAN, EMSAM, TRINTELLIX, PAXIL, PEXEVA, FETZIMA, or FETZIMA TITRATION PACK if enrollee has a paid claim for at least a 21 days' supply of MIRTAZAPINE, MIRTAZAPINE ODT, PHENELZINE SULFATE, TRAZODONE HCL, CITALOPRAM HYDROBROMIDE, ESCITALOPRAM OXALATE, FLUOXETINE HCL, FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE ER, PAROXETINE HCL, PAROXETINE HCL ER, SERTRALINE HCL, DULOXETINE HCL, VENLAFAXINE HCL, VENLAFAXINE HCL ER, AMITRIPTYLINE HCL, AMOXAPINE, DOXEPIN HCL, IMIPRAMINE HCL, NORTRIPTYLINE HCL, PROTRIPTYLINE HCL, BUPROPION HCL, or BUPROPION HCL SR in the past 365 days. Otherwise, Step 2 medications require a step therapy exception request indicating: (1) history of inadequate treatment response with Step 1 Antidepressant, OR (2) history of adverse event with Step 1 Antidepressant, OR (3) Step 1 Antidepressant is contraindicated. 1

ATOPIC DERMATITIS ELIDEL CREAM 1 % EXTERNAL tacrolimus ointment 0.03 % external tacrolimus ointment 0.1 % external Patient needs to have a paid claim for at least a 21 days' supply each of at least TWO formulary topical corticosteroids 2

ATYPICALS clozapine tablet dispersible 100 mg oral clozapine tablet dispersible 12.5 mg oral clozapine tablet dispersible 150 mg oral clozapine tablet dispersible 200 mg oral clozapine tablet dispersible 25 mg oral FANAPT TABLET 1 MG ORAL FANAPT TABLET 10 MG ORAL FANAPT TABLET 12 MG ORAL FANAPT TABLET 2 MG ORAL FANAPT TABLET 4 MG ORAL FANAPT TABLET 6 MG ORAL FANAPT TABLET 8 MG ORAL FANAPT TITRATION PACK TABLET 1 & 2 & 4 & 6 MG ORAL GEODON SOLUTION RECONSTITUTED 20 MG INTRAMUSCULAR INVEGA SUSTENNA SUSPENSION 117 MG/0.75ML INTRAMUSCULAR INVEGA SUSTENNA SUSPENSION 156 MG/ML INTRAMUSCULAR INVEGA SUSTENNA SUSPENSION 234 MG/1.5ML INTRAMUSCULAR INVEGA SUSTENNA SUSPENSION 39 MG/0.25ML INTRAMUSCULAR INVEGA SUSTENNA SUSPENSION 78 MG/0.5ML INTRAMUSCULAR INVEGA TRINZA SUSPENSION 273 MG/0.875ML INTRAMUSCULAR INVEGA TRINZA SUSPENSION 410 MG/1.315ML INTRAMUSCULAR INVEGA TRINZA SUSPENSION 546 MG/1.75ML INTRAMUSCULAR INVEGA TRINZA SUSPENSION 819 MG/2.625ML INTRAMUSCULAR paliperidone er tablet extended release 24 hour 1.5 mg oral paliperidone er tablet extended release 24 hour 3 mg oral paliperidone er tablet extended release 24 hour 6 mg oral paliperidone er tablet extended release 24 hour 9 mg oral RISPERDAL CONSTA SUSPENSION RECONSTITUTED 12.5 MG INTRAMUSCULAR RISPERDAL CONSTA SUSPENSION RECONSTITUTED 25 MG INTRAMUSCULAR RISPERDAL CONSTA SUSPENSION RECONSTITUTED 37.5 MG INTRAMUSCULAR RISPERDAL CONSTA SUSPENSION RECONSTITUTED 50 MG INTRAMUSCULAR SAPHRIS TABLET SUBLINGUAL 10 MG SUBLINGUAL SAPHRIS TABLET SUBLINGUAL 2.5 MG SUBLINGUAL SAPHRIS TABLET SUBLINGUAL 5 MG SUBLINGUAL VERSACLOZ SUSPENSION 50 MG/ML ORAL 3

Claim will pay automatically for FANAPT, FANAPT TITRATION PACK, PALIPERIDONE, INVEGA SUSTENNA, INVEGA TRINZA, RISPERDAL CONSTA, VERSACLOZ, CLOZAPINE ODT, SAPHRIS, or GEODON if enrollee has a paid claim for at least a 21 days' supply of a Latuda in the past 365 days. Otherwise, Step 2 Antipsychotics require a step therapy exception request indicating any ONE of the following: (1) diagnosis that is not covered by Latuda (i.e. Acute treatment of agitation for Geodon injection),or (2) history of inadequate treatment response with Latuda, OR (3) history of adverse event with Latuda, OR (4) Latuda is contraindicated. 4

FENTANYL fentanyl patch 72 hour 100 mcg/hr transdermal fentanyl patch 72 hour 12 mcg/hr transdermal fentanyl patch 72 hour 25 mcg/hr transdermal fentanyl patch 72 hour 37.5 mcg/hr transdermal fentanyl patch 72 hour 50 mcg/hr transdermal fentanyl patch 72 hour 62.5 mcg/hr transdermal fentanyl patch 72 hour 75 mcg/hr transdermal fentanyl patch 72 hour 87.5 mcg/hr transdermal Claim will pay automatically for Fentanyl patches if enrollee has paid claims history of 21 days' supply in the past 365 days of Morphine ER tablets (MS Contin generic only), Methadone, or Oxycodone ER. Otherwise, the drug requires a step therapy exception request indicating any ONE of the following: (1) history of inadequate treatment response to Morphine ER tablets (MS Contin generic only), Methadone, or Oxycodone ER OR (2) history of adverse event with Morphine ER tablets (MS Contin generic only), Methadone, or Oxycodone ER OR (3) Morphine ER, Methadone, or Oxycodone ER are contraindicated. 5

IMMUNOMODULATORS ACTEMRA SOLUTION 200 MG/10ML INTRAVENOUS ACTEMRA SOLUTION 400 MG/20ML INTRAVENOUS ACTEMRA SOLUTION 80 MG/4ML INTRAVENOUS ACTEMRA SOLUTION PREFILLED SYRINGE 162 MG/0.9ML CIMZIA KIT 2 X 200 MG CIMZIA PREFILLED KIT 2 X 200 MG/ML COSENTYX 300 DOSE SOLUTION PREFILLED SYRINGE 150 MG/ML COSENTYX SENSOREADY 300 DOSE SOLUTION AUTO-INJECTOR 150 MG/ML KINERET SOLUTION PREFILLED SYRINGE 100 MG/0.67ML ORENCIA CLICKJECT SOLUTION AUTO-INJECTOR 125 MG/ML ORENCIA SOLUTION PREFILLED SYRINGE 125 MG/ML ORENCIA SOLUTION PREFILLED SYRINGE 50 MG/0.4ML ORENCIA SOLUTION PREFILLED SYRINGE 87.5 MG/0.7ML ORENCIA SOLUTION RECONSTITUTED 250 MG INTRAVENOUS OTEZLA TABLET 30 MG ORAL SIMPONI ARIA SOLUTION 50 MG/4ML INTRAVENOUS SIMPONI SOLUTION AUTO- INJECTOR 100 MG/ML SIMPONI SOLUTION AUTO- INJECTOR 50 MG/0.5ML SIMPONI SOLUTION PREFILLED SYRINGE 100 MG/ML SIMPONI SOLUTION PREFILLED SYRINGE 50 MG/0.5ML STELARA SOLUTION 45 MG/0.5ML STELARA SOLUTION PREFILLED SYRINGE 45 MG/0.5ML STELARA SOLUTION PREFILLED SYRINGE 90 MG/ML XELJANZ TABLET 5 MG ORAL 6

Claim will pay automatically for Actemra, Cimzia, Kineret, Orencia, Otezla, Simponi, Stelara, Cosentyx or Xeljanz if enrollee has a paid claim for at least a 21 days' supply of Enbrel AND Humira in the past 365 days. Enrollee does NOT need history of Humira prior to Actemra, Cimzia, Kineret, Orencia, Otezla, Simponi, Stelara, Cosentyx or Xeljanz if diagnosed with Polyarticular Juvenile Idiopathic Arthritis (PJIA). Enrollee does NOT need history of Enbrel prior to Actemra, Cimzia, Kineret, Orencia, Otezla, Simponi, Stelara, Cosentyx or Xeljanz if diagnosed with Crohns Disease (CD), Ulcerative Colitis (UC), Juvenile Idiopathic arthritis (JIA) or Systemic Juvenile Idiopathic arthritis (SJIA). Otherwise, Actemra, Cimzia, Kineret, Orencia, Otezla, Simponi, Stelara, Cosentyx or Xeljanz requires a step therapy exception request indicating: (1) history of inadequate treatment response with Enbrel AND Humira, OR (2) history of adverse event with Enbrel AND Humira, OR (3) Enbrel AND Humira is contraindicated. For diagnosis cryopyrin-associated periodic syndromes, Kineret will be approved. For Giant Cell Arteritis, Actemra will be approved. 7

IMMUNOSUPPRESSANTS ASTAGRAF XL CAPSULE EXTENDED RELEASE 24 HOUR 0.5 MG ORAL ASTAGRAF XL CAPSULE EXTENDED RELEASE 24 HOUR 1 MG ORAL ASTAGRAF XL CAPSULE EXTENDED RELEASE 24 HOUR 5 MG ORAL AZASAN TABLET 100 MG ORAL AZASAN TABLET 75 MG ORAL NULOJIX SOLUTION RECONSTITUTED 250 MG INTRAVENOUS ZORTRESS TABLET 0.25 MG ORAL ZORTRESS TABLET 0.5 MG ORAL ZORTRESS TABLET 0.75 MG ORAL Claim will pay automatically for Non-Preferred Brand Immunosuppressants (i.e. Astagraf, Azasan, Nulojix, or Zortress) if enrollee has a paid claim for at least a 21 days' supply of a CYCLOSPORINE, CYCLOSPORINE MODIFIED, GENGRAF, MYCOPHENOLATE MOFETIL, MYCOPHENOLIC ACID DR, TACROLIMUS, or AZATHIOPRINE in the past 365 days. Otherwise, Non-Preferred Brand Immunosuppressants require a step therapy exception request indicating: (1) history of inadequate treatment response with Step 1 Immunosuppressants, OR (2) history of adverse event with Step 1 Immunosuppressants, OR (3) Step 1 Immunosuppressants is contraindicated. 8

LIVALO LIVALO TABLET 1 MG ORAL LIVALO TABLET 2 MG ORAL LIVALO TABLET 4 MG ORAL Claim will pay automatically for Livalo if enrollee has a paid claim for at least a 21 days' supply of atorvastatin or simvastatin in the past 365 days. Otherwise Livalo requires a step therapy exception request indicating: (1) history of inadequate treatment response with step 1 statins OR (2) history of adverse event with step 1 statins OR (3) step 1 statins are contraindicated. 9

MS THERAPY AMPYRA TABLET EXTENDED RELEASE 12 HOUR 10 MG ORAL Claim will pay automatically for Ampyra if enrollee has a paid claim for at least a 21 days' supply of glatiramer acetate, Betaseron, or Gilenya in the past 365 days. Otherwise, Ampyra requires a step therapy exception request indicating: (1) history of inadequate treatment response with glatiramer acetate, Betaseron, or Gilenya OR (2) history of adverse event with glatiramer acetate, Betaseron, or Gilenya OR (3) glatiramer acetate, Betaseron, or Gilenya are contraindicated. 10

OXYCODONE ER oxycodone hcl er tablet er 12 hour abusedeterrent 10 mg oral oxycodone hcl er tablet er 12 hour abusedeterrent 15 mg oral oxycodone hcl er tablet er 12 hour abusedeterrent 20 mg oral oxycodone hcl er tablet er 12 hour abusedeterrent 30 mg oral oxycodone hcl er tablet er 12 hour abusedeterrent 40 mg oral oxycodone hcl er tablet er 12 hour abusedeterrent 60 mg oral oxycodone hcl er tablet er 12 hour abusedeterrent 80 mg oral Claim will pay automatically for oxycodone ER if enrollee has paid claims history of 21 days' supply in the past 365 days of Morphine ER tablets (MS Contin generic only) or Methadone. Otherwise, the drug requires a step therapy exception request indicating any ONE of the following: (1) history of inadequate treatment response to Morphine ER tablets (MS Contin generic only) or Methadone OR (2) history of adverse event with Morphine ER tablets (MS Contin generic only) or Methadone OR (3) Morphine ER (MS Contin generic only) or Methadone are contraindicated. 11

PRADAXA PRADAXA CAPSULE 110 MG ORAL PRADAXA CAPSULE 150 MG ORAL PRADAXA CAPSULE 75 MG ORAL Claim will pay automatically for Pradaxa if enrollee has a paid claim for at least a 21 days' supply of Xarelto or Eliquis in the past 365 days. Otherwise, Pradaxa requires a step therapy exception request indicating: (1) History of inadequate treatment response with Xarelto or Eliquis, OR (2) History of adverse event with Xarelto or Eliquis, OR (3) Xarelto or Eliquis is contraindicated. 12

PROLIA PROLIA SOLUTION 60 MG/ML Patient needs to have a paid claim for at least a 21 days' supply of one Step 1 drug (alendronate, ibandronate, pamidronate, risedronate, or zoledronic acid) prior to filling a Prolia. For osteoporosis prophylaxis in men at high risk for bone fractures after receiving androgen deprivation therapy for nonmetastatic prostate cancer and in women at high risk for bone fractures after receiving adjuvant aromatase inhibitor therapy for breast cancer, Prolia will be approved. 13

RELISTOR MOVANTIK TABLET 12.5 MG ORAL MOVANTIK TABLET 25 MG ORAL RELISTOR SOLUTION 12 MG/0.6ML RELISTOR SOLUTION 12 MG/0.6ML (0.6ML SYRINGE) RELISTOR SOLUTION 8 MG/0.4ML Claim will pay automatically for Relistor OR Movantik if enrollee has a paid claim for at least a 21 days' supply of Amitiza in the past 365 days. Otherwise, Relistor OR Movantik requires a step therapy exception request indicating: (1) history of inadequate treatment response with Amitiza, OR (2) history of adverse event with Amitiza, OR (3) Amitiza is contraindicated. For patients with advanced illness who are receiving palliative care, Relistor will be approved. 14

UCERIS UCERIS FOAM 2 MG/ACT RECTAL UCERIS TABLET EXTENDED RELEASE 24 HOUR 9 MG ORAL Claim will pay automatically for Uceris if enrollee has a paid claim for at least a 21 days' supply of any formulary corticosteroid used to treat ulcerative colitis in the past 365 days. Otherwise, Uceris requires a step therapy exception request indicating: (1) history of inadequate treatment response with formulary corticosteroid used to treat ulcerative colitis, OR (2) history of adverse event with formulary corticosteroid used to treat ulcerative colitis, OR (3) formulary corticosteroid used to treat ulcerative colitis is contraindicated. 15

ULORIC ULORIC TABLET 40 MG ORAL ULORIC TABLET 80 MG ORAL Claim will pay automatically for Uloric if enrollee has a paid claim for at least a 21 days' supply of Allopurinol in the past 365 days. Otherwise, Uloric requires a step therapy exception request indicating: (1) history of inadequate treatment response with Allopurinol, OR (2) history of adverse event with Allopurinol, OR (3) Allopurinol is contraindicated. 16

XTANDI XTANDI CAPSULE 40 MG ORAL Claim will pay automatically for Xtandi if enrollee has a paid claim for at least a 21 days' supply of Zytiga in the past 365 days. Otherwise, Xtandi requires a step therapy exception request indicating: (1) history of inadequate treatment response with Zytiga OR (2) history of adverse event with Zytiga OR (3) Zytiga is contraindicated. 17

Alphabetical Listing A ACTEMRA SOLUTION 200 MG/10ML INTRAVENOUS... 6, 7 ACTEMRA SOLUTION 400 MG/20ML INTRAVENOUS... 6, 7 ACTEMRA SOLUTION 80 MG/4ML INTRAVENOUS... 6, 7 ACTEMRA SOLUTION PREFILLED SYRINGE 162 MG/0.9ML... 6, 7 AMPYRA TABLET EXTENDED RELEASE 12 HOUR 10 MG ORAL... 10 ASTAGRAF XL CAPSULE EXTENDED RELEASE 24 HOUR 0.5 MG ORAL... 8 ASTAGRAF XL CAPSULE EXTENDED RELEASE 24 HOUR 1 MG ORAL... 8 ASTAGRAF XL CAPSULE EXTENDED RELEASE 24 HOUR 5 MG ORAL... 8 AZASAN TABLET 100 MG ORAL... 8 AZASAN TABLET 75 MG ORAL... 8 C CIMZIA KIT 2 X 200 MG... 6, 7 CIMZIA PREFILLED KIT 2 X 200 MG/ML... 6, 7 clozapine tablet dispersible 100 mg oral. 3, 4 clozapine tablet dispersible 12.5 mg oral 3, 4 clozapine tablet dispersible 150 mg oral. 3, 4 clozapine tablet dispersible 200 mg oral. 3, 4 clozapine tablet dispersible 25 mg oral... 3, 4 COSENTYX 300 DOSE SOLUTION PREFILLED SYRINGE 150 MG/ML... 6, 7 COSENTYX SENSOREADY 300 DOSE SOLUTION AUTO-INJECTOR 150 MG/ML... 6, 7 E ELIDEL CREAM 1 % EXTERNAL... 2 EMSAM PATCH 24 HOUR 12 MG/24HR TRANSDERMAL... 1 EMSAM PATCH 24 HOUR 6 MG/24HR TRANSDERMAL... 1 EMSAM PATCH 24 HOUR 9 MG/24HR TRANSDERMAL... 1 F FANAPT TABLET 1 MG ORAL... 3, 4 FANAPT TABLET 10 MG ORAL... 3, 4 FANAPT TABLET 12 MG ORAL... 3, 4 FANAPT TABLET 2 MG ORAL... 3, 4 FANAPT TABLET 4 MG ORAL... 3, 4 FANAPT TABLET 6 MG ORAL... 3, 4 FANAPT TABLET 8 MG ORAL... 3, 4 FANAPT TITRATION PACK TABLET 1 & 2 & 4 & 6 MG ORAL... 3, 4 fentanyl patch 72 hour 100 mcg/hr transdermal... 5 fentanyl patch 72 hour 12 mcg/hr transdermal... 5 fentanyl patch 72 hour 25 mcg/hr transdermal... 5 fentanyl patch 72 hour 37.5 mcg/hr transdermal... 5 fentanyl patch 72 hour 50 mcg/hr transdermal... 5 fentanyl patch 72 hour 62.5 mcg/hr transdermal... 5 fentanyl patch 72 hour 75 mcg/hr transdermal... 5 fentanyl patch 72 hour 87.5 mcg/hr transdermal... 5 FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 120 MG ORAL... 1 FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 20 MG ORAL... 1 FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 40 MG ORAL... 1 FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 80 MG ORAL... 1 FETZIMA TITRATION CAPSULE ER 24 HOUR THERAPY PACK 20 & 40 MG ORAL... 1 G GEODON SOLUTION RECONSTITUTED 20 MG INTRAMUSCULAR... 3, 4 I INVEGA SUSTENNA SUSPENSION 117 MG/0.75ML INTRAMUSCULAR... 3, 4 INVEGA SUSTENNA SUSPENSION 156 MG/ML INTRAMUSCULAR... 3, 4 18

INVEGA SUSTENNA SUSPENSION 234 MG/1.5ML INTRAMUSCULAR... 3, 4 INVEGA SUSTENNA SUSPENSION 39 MG/0.25ML INTRAMUSCULAR... 3, 4 INVEGA SUSTENNA SUSPENSION 78 MG/0.5ML INTRAMUSCULAR... 3, 4 INVEGA TRINZA SUSPENSION 273 MG/0.875ML INTRAMUSCULAR... 3, 4 INVEGA TRINZA SUSPENSION 410 MG/1.315ML INTRAMUSCULAR... 3, 4 INVEGA TRINZA SUSPENSION 546 MG/1.75ML INTRAMUSCULAR... 3, 4 INVEGA TRINZA SUSPENSION 819 MG/2.625ML INTRAMUSCULAR... 3, 4 K KINERET SOLUTION PREFILLED SYRINGE 100 MG/0.67ML... 6, 7 L LIVALO TABLET 1 MG ORAL... 9 LIVALO TABLET 2 MG ORAL... 9 LIVALO TABLET 4 MG ORAL... 9 M MARPLAN TABLET 10 MG ORAL... 1 MOVANTIK TABLET 12.5 MG ORAL. 14 MOVANTIK TABLET 25 MG ORAL... 14 N NULOJIX SOLUTION RECONSTITUTED 250 MG INTRAVENOUS... 8 O ORENCIA CLICKJECT SOLUTION AUTO-INJECTOR 125 MG/ML... 6, 7 ORENCIA SOLUTION PREFILLED SYRINGE 125 MG/ML... 6, 7 ORENCIA SOLUTION PREFILLED SYRINGE 50 MG/0.4ML... 6, 7 ORENCIA SOLUTION PREFILLED SYRINGE 87.5 MG/0.7ML... 6, 7 ORENCIA SOLUTION RECONSTITUTED 250 MG INTRAVENOUS... 6, 7 OTEZLA TABLET 30 MG ORAL... 6, 7 oxycodone hcl er tablet er 12 hour abusedeterrent 10 mg oral... 11 oxycodone hcl er tablet er 12 hour abusedeterrent 15 mg oral... 11 oxycodone hcl er tablet er 12 hour abusedeterrent 20 mg oral... 11 oxycodone hcl er tablet er 12 hour abusedeterrent 30 mg oral... 11 oxycodone hcl er tablet er 12 hour abusedeterrent 40 mg oral... 11 oxycodone hcl er tablet er 12 hour abusedeterrent 60 mg oral... 11 oxycodone hcl er tablet er 12 hour abusedeterrent 80 mg oral... 11 P paliperidone er tablet extended release 24 hour 1.5 mg oral... 3, 4 paliperidone er tablet extended release 24 hour 3 mg oral... 3, 4 paliperidone er tablet extended release 24 hour 6 mg oral... 3, 4 paliperidone er tablet extended release 24 hour 9 mg oral... 3, 4 PAXIL SUSPENSION 10 MG/5ML ORAL... 1 PEXEVA TABLET 10 MG ORAL... 1 PEXEVA TABLET 20 MG ORAL... 1 PEXEVA TABLET 30 MG ORAL... 1 PEXEVA TABLET 40 MG ORAL... 1 PRADAXA CAPSULE 110 MG ORAL.. 12 PRADAXA CAPSULE 150 MG ORAL.. 12 PRADAXA CAPSULE 75 MG ORAL... 12 PROLIA SOLUTION 60 MG/ML... 13 R RELISTOR SOLUTION 12 MG/0.6ML... 14 RELISTOR SOLUTION 12 MG/0.6ML (0.6ML SYRINGE)... 14 RELISTOR SOLUTION 8 MG/0.4ML... 14 RISPERDAL CONSTA SUSPENSION RECONSTITUTED 12.5 MG INTRAMUSCULAR... 3, 4 19

RISPERDAL CONSTA SUSPENSION RECONSTITUTED 25 MG INTRAMUSCULAR... 3, 4 RISPERDAL CONSTA SUSPENSION RECONSTITUTED 37.5 MG INTRAMUSCULAR... 3, 4 RISPERDAL CONSTA SUSPENSION RECONSTITUTED 50 MG INTRAMUSCULAR... 3, 4 S SAPHRIS TABLET SUBLINGUAL 10 MG SUBLINGUAL... 3, 4 SAPHRIS TABLET SUBLINGUAL 2.5 MG SUBLINGUAL... 3, 4 SAPHRIS TABLET SUBLINGUAL 5 MG SUBLINGUAL... 3, 4 SIMPONI ARIA SOLUTION 50 MG/4ML INTRAVENOUS... 6, 7 SIMPONI SOLUTION AUTO-INJECTOR 100 MG/ML... 6, 7 SIMPONI SOLUTION AUTO-INJECTOR 50 MG/0.5ML... 6, 7 SIMPONI SOLUTION PREFILLED SYRINGE 100 MG/ML... 6, 7 SIMPONI SOLUTION PREFILLED SYRINGE 50 MG/0.5ML... 6, 7 STELARA SOLUTION 45 MG/0.5ML... 6, 7 STELARA SOLUTION PREFILLED SYRINGE 45 MG/0.5ML... 6, 7 STELARA SOLUTION PREFILLED SYRINGE 90 MG/ML... 6, 7 T tacrolimus ointment 0.03 % external... 2 tacrolimus ointment 0.1 % external... 2 TRINTELLIX TABLET 10 MG ORAL... 1 TRINTELLIX TABLET 20 MG ORAL... 1 TRINTELLIX TABLET 5 MG ORAL... 1 U UCERIS FOAM 2 MG/ACT RECTAL... 15 UCERIS TABLET EXTENDED RELEASE 24 HOUR 9 MG ORAL... 15 ULORIC TABLET 40 MG ORAL... 16 ULORIC TABLET 80 MG ORAL... 16 V VERSACLOZ SUSPENSION 50 MG/ML ORAL... 3, 4 X XELJANZ TABLET 5 MG ORAL... 6, 7 XTANDI CAPSULE 40 MG ORAL... 17 Z ZORTRESS TABLET 0.25 MG ORAL... 8 ZORTRESS TABLET 0.5 MG ORAL... 8 ZORTRESS TABLET 0.75 MG ORAL... 8 20